Posted Date: January 11, 2011
Several major health insurers say they will continue paying for Genentech’s Avastin for the treatment of breast cancer, based on a recommendation from the National Comprehensive Cancer Network, Bloomberg Businessweek reports (Larkin, Bloomberg Businessweek, 1/10).
Several major health insurers say they will continue paying for Genentech’s Avastin for the treatment of breast cancer, based on a recommendation from the National Comprehensive Cancer Network, Bloomberg Businessweek reports (Larkin, Bloomberg Businessweek, 1/10).
In December 2010, the FDA announced its plan to revoke the drug’s breast cancer approval status because of evidence that it does not prolong life expectancy for women with the disease and that its risk to benefit ratio was not acceptable.